Firms in the pharmaceutical industry have received a major boost in the finer details of the latest Budget announcement by chancellor George Osborne, it is claimed.
Biotechnology analyst Savvas Neophytou believes that the latest Budget is "small business-friendly", which will help firms struggling to stay afloat in the sector, Proactive Investors reports.
Provisions made by Mr Osborne that will help pharmaceutical firms include an increase in the research and development tax credit, which has increased from 175 per cent to 200 per cent and will rise again to 225 per cent in 2012.
Read the rest of this entry »
A new collaboration between the European Medicines Agency and US Food and Drug Administration could have wide ramifications for how pharmaceuticals approach the research, development and manufacture of drugs.
The new pilot programme to evaluate the pervasiveness of a Quality by Design (QbD) approach to developing products will be launched on April 1st and will involve an assessment of a number of areas relevant to QbD, such as development, design space and real-time testing.
New marketing authorisation applications and scientific advice requests will also fall under the pilot, which will only include chemical entities and is set to run until March 31st 2014.
Read the rest of this entry »
International firms looking to build a new chemicals manufacturing facility should think about placing it in Scotland, it has been suggested.
According to research from Scottish Development International, the country offers the best quality-to-cost ratio in Europe, Plastics and Rubber Weekly reports.
The group observed more than 50 measures of quality and ten of cost, comparing the results to competitor locations in Manchester, Dresden and Frankfurt.
Read the rest of this entry »
A workshop helping firms to identify risks and inefficiencies in their powder processing techniques will take place next month.
The Wolfson Centre for Bulk Solids Handling Technology at the University of Greenwich will run the course, according to Processing Talk.
With a focus on assisting companies with effective powder storage and the factors affecting material performance, the April 12th workshop will hopefully allow delegates to improve their processing methods and, therefore, their profit margins.
Read the rest of this entry »
The baking industry needs to brace itself for further volatility in the bread wheat market, an expert has suggested.
Home Grown Cereals Authority senior analyst Jack Watts recently told the Milling Wheat Conference that Russian harvests and the influence of currency markets will continue to create unpredictability in the price of wheat.
Mr Watts went on to explain to British Baker Magazine after the event that feed grain acts as a "price floor" for the rest of the market.
Read the rest of this entry »
The transfer of newly-developed technology to medicine and other health products needs to be improved across the pharmaceutical industry, according to a new paper.
There is a growing disparity between innovations reaching the market in developed "middle income" economies and developing nations, findings by the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) indicate.
Governments in low-income economies have been urged to improve links with pharmaceutical technology partners to facilitate better transfer to local markets.
Read the rest of this entry »
The changing face of NHS procurement could mean further changes to the way processors involved in the pharmaceutical supply chain operate.
Eight out of ten GPs believe that pharmacists should have a bigger role in commissioning orders, according to a new survey by Pfizer.
Half of those polled indicated that closer involvement of pharmacists in commissioning decisions would improve the effectiveness of patient-focused care, while improving cost-efficiency.
Read the rest of this entry »
European firms in the chemical and powder processing industry may soon have to apply for special permission to use six chemicals, which are being phased out by authorities.
The European Commission has committed to ban the six substances within the next three to five years unless individual companies are granted permission for their use.
5-ter-butyl-2,4,6-trinito-m-xylene (musk xylene), 4,4'-diaminodiphenylmethane (MDA), hexabromocyclododecane (HBCDD), bis(2-ethylexyl) phthalate (DEHP), benzyl butyl phthalate (BBP) and dibutyl phthalate (DBP) have all been designated as either carcinogenic, toxic for reproduction, or persist and accumulate in the environment and living organisms.
Read the rest of this entry »
Firms in the pharmaceutical industry have received a major boost in the finer details of the latest Budget announcement by chancellor George Osborne, it is claimed.
